Drug Trial Radar · NCT02221102
Edoxaban for TIA and Acute Minor Stroke
Last checked: Nov 20, 2026Latest source record: Aug 20, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
3,700
Planned (sponsor's estimate)
Start
Dec 2013
Primary completion
Jun 2015
Study completion Jun 2016
Sponsor
- Lead sponsor
- Xijing HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 20, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Transient ischemic attack (TIA) or minor ischemic stroke has a high risk of early recurrent stroke. As the golden standard, aspirin effect modestly on acute ischemic stroke, and slightly increase the risk of intracerebral hemorrhage. Recently, edoxaban, a new oral anticoagulant, is proved to be as effective as traditional anticoagulants, while carrying significantly less risk of intracranial hemorrhage. This trial is a randomized, double-blind, multicenter, controlled clinical trial in China. The investigators will assess the hypothesis that a 30-days edoxaban regimen is superior to aspirin alone for the treatment of high-risk patients with acute nondisabling cerebrovascular event.
Conditions
- Ischemia
- Stroke
- Cerebral Infarction
Interventions
AspirinDrug
non-steroidal anti-inflammatory drugs
edoxabanDrug
orally active direct factor Xa inhibitor
placeboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- percentage of patients with new stroke (ischemic or hemorrhage)Time frame: 90 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Xijing Hospital
Xi'an, Shaanxi, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.